KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Retained Earnings (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Retained Earnings for 15 consecutive years, with -$44000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 100.01% to -$44000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$44000.0 through Dec 2025, down 100.01% year-over-year, with the annual reading at -$44000.0 for FY2025, 100.01% down from the prior year.
  • Retained Earnings for Q4 2025 was -$44000.0 at Supernus Pharmaceuticals, down from $522.0 million in the prior quarter.
  • The five-year high for Retained Earnings was $567.1 million in Q2 2025, with the low at -$4.0 million in Q3 2022.
  • Average Retained Earnings over 5 years is $201.6 million, with a median of $4.8 million recorded in 2021.
  • The sharpest move saw Retained Earnings tumbled 308.58% in 2022, then skyrocketed 669106.41% in 2025.
  • Over 5 years, Retained Earnings stood at $1.5 million in 2021, then plummeted by 308.58% to -$3.2 million in 2022, then soared by 81.53% to -$593000.0 in 2023, then skyrocketed by 93932.38% to $556.4 million in 2024, then plummeted by 100.01% to -$44000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$44000.0, $522.0 million, and $567.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.